JAZZ Add to watchlist $236.49 +1.11 (+0.47%) Last updated: May 31, 2026 03:50
52-Week Range
$236.49
$105.00 $236.49 $243.32

Fundamentals Overview

Jazz Pharmaceuticals plc is near the high of its 52-week range with premium valuation, trading relatively flat today.

Valuation premium

P/E 530 P/B 3.23 P/S 3.34

Intrinsic value (DCF)

+115.7% upside vs price

Profitability

Net margin 0.7%

Risk (Beta)

0.27 — lower vol

Earnings & growth

EPS $0.45 Rev -10.8% Profit +44.1% vs prior qtr

BullzEye Analysis

Our composite tilts Buy on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell
Buy
Buy — 76% confidence Risk: Lower Volatility — Beta 0.27. Diversify and only invest what you can afford to lose.

Supporting (Buy):

DCF +115.7% upside vs price · Analyst grade: B · 3M vs S&P 500: +11% · 3M vs Healthcare sector: +25.4%

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap
$14.84B
P/E (TTM)
530.02
EPS (TTM)
$0.45
Dividend Yield
N/A
52-Week Range
$105.00 - $243.32
Volume vs Avg
N/A
Beta
0.27

About

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of catap...
Sector: Healthcare
Headquarters: IE
Employees: 2,800
IPO Date: Jun 2007
Beta: 0.27 (Less volatile than market)

Ratings & Grades at a Glance

Overall rating: B. Recent institutional grades: mixed. Current institutional positions: Buy: 9, Neutral: 1, Outperform: 6, Overweight: 14.

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

DCF vs price: DCF estimate is $510.22; current price is $236.49. That’s a +115.7% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.

Metric Value
Valuation
P/E (TTM) 530.02
DCF value (model) $510.22 (115.7% upside)
PEG (TTM) N/A
P/B (TTM) 3.23
P/S (TTM) 3.34
P/FCF (TTM) 11.91
Liquidity & enterprise
Current Ratio (TTM) 2.04
Quick Ratio (TTM) 1.85
Cash Ratio (TTM) 0.82
Profitability
ROE (TTM) N/A
ROA (TTM) N/A
Revenue growth (YoY) N/A
Net margin (TTM) 0.66%
Gross margin (TTM) 84.12%
Operating margin (TTM) 11.13%
Debt to equity (TTM) N/A

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for JAZZ.

Analyst Sentiment at a Glance

B Sentiment Mixed
Buy 9Neutral 1Outperform 6Overweight 14
1 upgrade, 1 downgrade
Price Target Consensus
Current $236.49
Median $248.50
Consensus $257.63
Low consensus $229.00
High consensus $307.00

Stock Grades (Institutions)

Institution Action Previous Grade New Grade Date
Barclays maintain Overweight Overweight 2026-05-27
Piper Sandler maintain Overweight Overweight 2026-05-22
UBS upgrade Neutral Buy 2026-05-19
RBC Capital maintain Outperform Outperform 2026-05-06
Barclays maintain Overweight Overweight 2026-05-06
Wells Fargo maintain Overweight Overweight 2026-05-06
TD Cowen maintain Buy Buy 2026-05-06
Leerink Partners maintain Outperform Outperform 2026-04-22
Barclays maintain Overweight Overweight 2026-04-20
Piper Sandler maintain Overweight Overweight 2026-03-19
Wells Fargo maintain Overweight Overweight 2026-02-25
B of A Securities maintain Buy Buy 2026-02-25
RBC Capital maintain Outperform Outperform 2026-02-25
Morgan Stanley maintain Overweight Overweight 2026-02-25
Truist Securities maintain Buy Buy 2026-01-12
Needham maintain Buy Buy 2026-01-12
Piper Sandler maintain Overweight Overweight 2025-12-10
UBS downgrade Buy Neutral 2025-11-24
Baird maintain Outperform Outperform 2025-11-18
Wells Fargo maintain Overweight Overweight 2025-11-18
B of A Securities maintain Buy Buy 2025-11-18
Morgan Stanley maintain Overweight Overweight 2025-11-17
RBC Capital maintain Outperform Outperform 2025-11-17
RBC Capital maintain Outperform Outperform 2025-11-06
JP Morgan maintain Overweight Overweight 2025-10-27
Morgan Stanley maintain Overweight Overweight 2025-10-20
Morgan Stanley maintain Overweight Overweight 2025-09-24
Goldman Sachs maintain Buy Buy 2025-08-29
Truist Securities maintain Buy Buy 2025-08-28
Needham maintain Buy Buy 2025-08-28